The problem is that there is no published literature on use of external beam radiation with gemcitabine + abraxane that provides a OS number. The best thing to use is the 2011 paper in this case.
They will only get FDA approval and US insurance coverage with a 2 arm study that shows this. It will be in my opinion a formality as there is a OS advantage, question is how much OS? I think 5 months is reasonable as that is what they showed in the previous study
The problem is that there is no published literature on use of...
Add to My Watchlist
What is My Watchlist?
 (20min delay)
|
|||||
|
Last
$1.00 |
Change
0.000(0.00%) |
Mkt cap ! $14.22M | |||
| Open | High | Low | Value | Volume |
| $1.00 | $1.01 | $1.00 | $16.29K | 16.28K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 4283 | $1.00 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $1.01 | 1249 | 1 |
View Market Depth
| Last trade - 10.08am 25/06/2025 (20 minute delay) ? |
| OSL (ASX) Chart |